NevenKYCoxBCosemansCGyselaersWPendersJPlusquinMet al
Those who continued the medication maintained or continued to lose weight, while those who stopped regained much of the weight lost, underscoring the need for long-term therapy.23 Longer-term outcomes were assessed in STEP 5, which extended treatment to 104 weeks and demonstrated sustained weight loss of approximately 15%.24 In East Asian populations, STEP 6 showed similar results, with participants achieving an average 12% to 13% weight loss over 68 weeks.25 STEP 7, a 44-week trial including participants from China, Hong Kong, Brazil, and South Korea, found that those on semaglutide lost an average of 12.1% of their body weight compared with 3.6% with placebo.26 Lastly, STEP 8 compared semaglutide with liraglutide and showed greater efficacy with semaglutide (15.8% vs 6.4% weight loss), as well as better tolerability and more convenient weekly dosing.27 Taken together, the STEP trials show that semaglutide consistently results in clinically meaningful weight loss across various populations and treatment conditions
You may also experience a short period of fatigue following your treatment as your body adjusts to the detoxifying process
Poster session II - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.03 - ATHEROSCLEROSIS P934 - ESOC25-565 ASSOCIATION OF THROMBOINFLAMMATORY BIOMARKERS WITH ATHEROSCLEROSIS: INSIGHTS FROM THE PRECISE STUDY Baoshan Qiu 1 , Yilong Wang 1 , Yilong Wang 1 1 Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Background and Aims: Atherosclerosis is a multifaceted disease with inflammation playing a pivotal role
